JP2023520516A5 - - Google Patents

Info

Publication number
JP2023520516A5
JP2023520516A5 JP2022560204A JP2022560204A JP2023520516A5 JP 2023520516 A5 JP2023520516 A5 JP 2023520516A5 JP 2022560204 A JP2022560204 A JP 2022560204A JP 2022560204 A JP2022560204 A JP 2022560204A JP 2023520516 A5 JP2023520516 A5 JP 2023520516A5
Authority
JP
Japan
Prior art keywords
individual
product according
pharmaceutical product
amino acid
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025626 external-priority patent/WO2021203030A2/en
Publication of JP2023520516A publication Critical patent/JP2023520516A/ja
Publication of JP2023520516A5 publication Critical patent/JP2023520516A5/ja
Pending legal-status Critical Current

Links

JP2022560204A 2020-04-03 2021-04-02 抗trem2抗体の使用方法 Pending JP2023520516A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005130P 2020-04-03 2020-04-03
US63/005,130 2020-04-03
US202063079810P 2020-09-17 2020-09-17
US63/079,810 2020-09-17
PCT/US2021/025626 WO2021203030A2 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies

Publications (2)

Publication Number Publication Date
JP2023520516A JP2023520516A (ja) 2023-05-17
JP2023520516A5 true JP2023520516A5 (https=) 2024-04-10

Family

ID=75674977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560204A Pending JP2023520516A (ja) 2020-04-03 2021-04-02 抗trem2抗体の使用方法

Country Status (11)

Country Link
US (1) US20230183341A1 (https=)
EP (1) EP4126953A2 (https=)
JP (1) JP2023520516A (https=)
KR (1) KR20230005848A (https=)
CN (1) CN115667308A (https=)
AU (1) AU2021247286A1 (https=)
BR (1) BR112022019892A2 (https=)
CA (1) CA3172451A1 (https=)
IL (1) IL296992A (https=)
MX (1) MX2022012182A (https=)
WO (1) WO2021203030A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3601358T5 (da) * 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
CN115003699A (zh) * 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
EP4347658A4 (en) * 2021-05-28 2025-06-04 Vigil Neuroscience, Inc. TREM2 AGONIST BIOMARKER AND METHODS OF USE THEREOF
AU2022307687A1 (en) * 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023164516A1 (en) * 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023192282A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CN117624360A (zh) 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7105825B2 (en) * 1999-04-14 2006-09-12 Juni Jack E Single photon emission computed tomography system
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3198933B1 (en) * 2014-09-26 2020-11-04 Sun Patent Trust Device-to-device wireless communication method and user equipment
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102425326B1 (ko) * 2016-05-20 2022-07-25 세다르스-신나이 메디칼 센터 알츠하이머병 및 관련 병태의 치료 또는 예방 방법
CN109641961A (zh) 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
DK3601358T5 (da) * 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CN115003699A (zh) * 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗trem2抗体の使用方法
WO2023164516A1 (en) * 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies

Similar Documents

Publication Publication Date Title
JP2023520516A5 (https=)
Kim et al. Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
JP2022058369A (ja) アルツハイマー病治療方法
JP7676556B2 (ja) 抗N3pGluアミロイドベータ抗体及びその使用
JP2010187674A5 (https=)
AU2022232936B2 (en) Anti-amyloid beta antibodies and uses thereof
CN109476730A (zh) 治疗阿尔茨海默病的方法
JP2024525559A (ja) アルツハイマー病治療用バイオマーカー
US20220135659A1 (en) Treatment of neonatal hypoxia including impairments or effects thereof
TW202231661A (zh) 安全投予抗tau抗體之方法
CN120583962A (zh) 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
WO2024054416A1 (en) Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease
JP2024540294A5 (https=)
US20240158486A1 (en) ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF
TW202541846A (zh) 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
CN116829582A (zh) 安全施用抗Tau抗体的方法
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
CN118786141A (zh) 使用p-tau181水平的治疗方法
Statements Amyloid-beta immunotherapy: the future for Alzheimer’s therapeutics?